

HEMOSENSE INC  
Form 8-K  
September 29, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

September 26, 2005

Date of Report (date of earliest event reported)

---

**HEMOSENSE, INC.**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-32541**  
(Commission File Number)

**77-0452938**  
(I.R.S. Employer  
Identification Number)

**651 River Oaks Parkway**

Edgar Filing: HEMOSENSE INC - Form 8-K

San Jose, California 95134

(Address of principal executive offices)

(408) 719-1393

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On September 26, 2005, Richard P. Powers was appointed to the Company's Board of Directors as a new sixth member of the Board. Mr. Powers will serve as a Class III director on the Board. Mr. Powers also has been appointed to the Company's Audit Committee, replacing Greg Ayers, who remains on the Board. Mr. Powers will also serve as chairman of the Audit Committee. The Company is issuing a press release regarding the appointment of Mr. Powers to the Company's Board of Directors. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

**(c) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of HemoSense, Inc. dated as of September 29, 2005.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**HEMOSENSE, INC.**

Date: September 29, 2005

By: /s/ James D. Merselis

---

James D. Merselis  
President and Chief Executive Officer